A new clinical trial is being offered for children and young adults with recurrent or progressive high-grade glioma (HGG) at Joseph M. Sanzari Children’s Hospital. As a member of the Pacific Pediatric Neuro-Oncology Consortium (PNOC), our hospital is participating in this groundbreaking PNOC trial studying the treatment of HGG, an aggressive, fast-growing type of brain tumor.
We are proud to say that Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center is one of only 12 hospitals in the country to offer this trial – and the only center in the New York metropolitan area. Tackle Kids Cancer supporters’ investment in our research helped lead us to becoming a PNOC hospital, which allows us to offer clinical trials like this one.
“High-grade gliomas account for approximately 10 percent of all brain tumors in children, and more research is needed to identify treatments that may improve long-term survival rates,” Derek Hanson, M.D., chief, Pediatric Neurology-Oncology, Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center and PNOC principal investigator.
“Immunotherapy has been shown to be a promising treatment for other types of cancer, and our goal with this study is to learn more about how and when immunotherapy could be used to provide new hope for children diagnosed with HGG.”
To learn more about the trial, please click here.